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Abstract:
Obstructive sleep apnea (OSA) and type 2 diabetes mellitus (T2DM) are both common diseases that 
present a burden to a remarkable number of individuals worldwide, and their incidence and prevalence 
are constantly raising. OSA and T2DM coexist very often, they have common independent predispos-
ing factors, and the main of them is obesity. However, they can share many other pathogenetic factors 
like chronic inflammation, oxidative stress, hormonal changes and autonomic nervous system disbal-
ance, which are discussed in this review. OSA and T2DM, when untreated or undertreated, may lead 
to the additive or synergistic effect in a patient, leading to accelerated development of atherosclerosis 
and its cardiovascular complications.
Recently, concomittant presence of OSA and T2DM was linked to possibility of higher incidence of 
colon cancer. As OSA, obesity and diabetes type 2 presen tindependent increased risk for cardiovas-
cular complications, cardiovascular morbidity and mortality, special focus should be put on the early 
recognition of OSA simptoms in the patients with T2DM, and vice versa, patients with OSA should 
be regularly checked for presence of glucose intolerance or insulin resistance, in order to prevent long-
term consequences.
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Sažetak:
Opstruktivna apneja u spavanju i dijabetes melitus tipa 2
Opstruktivna apneja u spavanju (OSA, prema engl. obstructive sleep apnea) i dijabetes melitus tipa 2 
(T2DM, prema engl. type 2 diabetes mellitus) česte su bolesti od kojih pati značajan broj bolesnika 
širom svijeta, a njihova incidencija i prevalencija su u neprestanom porastu.OSA i T2DM su vrlo često 
istovremeno prisutne kod istog bolesnika, te imaju zajedničke neovisne čimbenike rizika, od kojih je 
najvažniji pretilost. Osim toga, OSA i T2DM dijele i više čimbenika patogeneze, kao što su kronična 
upala, oksidativni stres, hormonalne promjene i poremećena ravnoteža autonomnog živčanog sustava, 
o kojima se raspravlja u ovom preglednom radu. Ukoliko se kod bolesnika OSA i T2DM ne liječe 
ili liječe neadekvatno, mogu aditivnim ili sinergističkim učinkom dovesti do ubrzanog razvoja ater-
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oskleroze i njezinih kardiovaskularnih i drugih komplikacija. Konkomitantna prisutnost OSA i T2DM 
je od nedavno povezana i većom incidencijom raka debelog crijeva. Budući da su OSA, pretilost i 
dijabetes tipa 2 neovisni čimbenici rizika za razvoj kardiovaskularnih komplikacija, kardiovaskularnog 
morbiditeta i mortaliteta, posebnu pozornost bi trebalo usmjeriti na rano prepoznavanje OSA-e kod 
bolesnika s T2DM- om, a s druge strane, kod bolesnika s OSA-om bi trebalo redovito kontrolirati 
eventualne znakove intolerancije glukoze ili inzulinske rezistencije, kako bi se što ranije i učinkovitije 
spriječile dugoročne posljedice tih bolesti.
Ključne riječi: apneja u spavanju, sindrom apneje, dijabetes
Introduction
Obstructive Sleep apnea (OSA) is a major health problem. 
Beside that it significantly lowers the quality of life 1, it increases 
risk for cardiovascular disease, metabolic syndrome and diabetes 
mellitus, contributing overall morbidity and mortality 1-5. In the 
light of new SARS-COV-2 pandemics, available data indicate 
that it might worsen the outcome and increase the death rate of 
the COVID-19 infection 6 It is estimated than 936 million indi-
viduals aged 30–69 years (men and women included) worldwide 
have OSA 7. Among this group, 425 million individuals have 
moderate to severe obstructive sleep apnea, estimated using crite-
ria based on number of apneic episodes of 15 or more events per 
hour. The latter group is considered as clinically more important, 
because the treatment is often required 7.
Diabetes mellitus is another world-wide burden, that decreases 
quality of life and increases risk for short-term and long-term 
complications, leading to higher morbidity and mortality 8. 
Although type I diabetes mellitus, caused by lack of insulin 
production, is a severe condition which, when untreated, leads 
to rapid metabolic impairment and death, type 2 diabetes 
mellitus in which combination of impaired insulin production 
and decreased ability of insulin-sensitive tissues to respond to 
insulin are present, is much more common (>90% of all DM 
cases) and its incidence is rapidly increasing especially in young 
population even in adolescents and children 8. T2DM epidem-
ics is mostly attributed to increase of obesity, caused by high-fat 
diet and sedentary lifestyle 9,10, and aging of population 11 Early 
onset of T2DM lowers the age of appearance of microvascular 
and macrovascular complications and shortens the individual’s 
life-span 9-12.
OSA and T2DM often overlap in the same patient, and share 
common comorbidities and risks, which can increase the mortal-
ity risk and demands for treatment 13-15. The aim of this review 
is to focus on some common aspects between OSA and T2DM, 
with special attention to metabolic factors in pathogenesis of 
these two conditions.
Clinical aspects 
Sleep apnea is a common sleep disorder characterized by absence 
of inspiratory airflow for periods for ≥10 seconds. Hypopnea is 
defined as reduction in airflow to ≥ 50% for periods for ≥10 sec-
onds. Both apnea and hypopnea usually may lead to intermittent 
drop of oxygen saturation, hypercapnia and decreased quality of 
sleep 5,15. Typical symptoms in a patient with sleep apnea include 
snoring in most of the sleep period, and, when awake, patients 
often complain about tiredness despite sleeping all night, with 
lack of concentration, morning headache or behavioural changes. 
Sleep apnea can be caused by 1. abnormal impulses transmis-
sion from central nervous system to respiratory muscles (central 
sleep apnea, CSA), and 2. collapsed airways or increased airway 
resistance that prevent airflow (obstructive sleep apnea, OSA). 
A distinct form of sleep apnea is complex sleep apnea syndrome 
(CompSAS), where CSA develops in patients with preexisting 
OSA, previously treated with a continuous positive airway pres-
sure (CPAP) device 16,17. The latter combination of both obstruc-
tive and central mechanisms, is considered as severe emergency 
condition. Obstructive sleep apnea (OSA) is the most common 
type of sleep apnea defined as temporary cessation or reduction of 
airflow caused by intermittent increase of upper airway resistance 
during respiratory effort in association with sleep fragmentation 
18,19. Although all OSA patients have certain level of impaired up-
per airway anatomy, since last 7 years four subphenotypes of OSA 
have been recognized, taking into account additional non-ana-
tomical factors: ineffective upper-airway dilator muscles influenc-
ing pharyngeal critical closing pressure (Pcrit), respiratory control 
instability (high loop gain), and upper airway recruitment and 
low repiratory arousal threshold 20, 21. This subdivision is impor-
tant for finding the best treatment approach 21 Increase of airway 
resistance may be caused by anatomic abnormalities (enlarged 
tonsils), decreased muscle tone in oropharyngeal or nasopharyn-
geal muscles, or, in most cases, accumulation of fat in the neck 
or pharyngeal tissue 19. Polysomnography (PSG) is a standard 
method for estimation of sleep apnea, and determining of sum of 
apneas or hypopneas per hour of sleep, known as apnea-hypopnea 
index (AHI) is required for diagnosis and assesment of OSA 
grade. AHI ≥ 5 per hour of sleep is considered abnormal, and 
increased daytime sleepines associated with abnormal AHI is typi-
cal for OSA. 22 OSA can be classified as mild, when AHI is 5-14 
events/hour of sleep, moderate (AHI 15-29), and severe (AHI ≥ 
30 per hour of sleep 23.
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Best and the first-line method for OSA treatment is an ap-
plication of continous positive airway pressure (CPAP) 8,9. The 
alternatives are oral appliances, surgical procedures and electri-
cal stimulation 9 These methods can be combined with lifestyle 
changes and obesity reduction 24, 25.
Epidemiology of sleep apnea and association 
with type 2 diabetes mellitus
OSA prevalence is increasing rapidly worldwide 7,26,27, which 
can be attributed mostly to increasing epidemics of obesity 28. 
In earlier investigations, it was estimated that in people with 
body mass index (BMI) 25-28, every 1 in 5 adults have at least 
mild OSA, while 1 of 15 adults have moderate or severe OSA 29. 
Newer studies that are based on different diagnostic criteria indi-
cate that in general population, prevalence of moderate to severe 
OSA ranges 49,7 % in men and 23,4 % in women 30 However, 
in obese adults OSA prevalence can reach 70%, and in adults 
with diabetes mellitus type 2 (T2DM) is 58-86% 26. As reported 
in Sleep AHEAD Study, the highest prevalence of OSA (86,6%) 
is found among individuals with T2DM with severe obesity 
and BMI ≥ 36,5 ± 5,8 kg/m2, while 30,5% obese T2DM had 
moderate OSA and 22,6 % had severe OSA 31. The prevalence 
of OSA in patients with T2DM is higher in White Europeans 
than in South Asia. 32 Moderate to severe sleep apnea is present 
in 46,3 % of patients with long-standing type I diabetes mellitus 
(DMT1) 33. This strongly suggests that association exists between 
sleep apnea, obesity and impaired glucose homeostasis 34. 
Severity of OSA is independently and positively correlated with 
increase of HbA1c levels 35 On the other side, OSA is consid-
ered as independent risk factor for T2DM, and both OSA and 
T2DM are important risk factors in patophysiology of metabolic 
syndrome and cardiovascular disease 15,19. According to several 
studies that have investigated association between OSA and 
obesity, neck circumference (NC) and visceral obesity are more 
related to OSA than BMI 36,37. In “Standards of Medical Care in 
Diabetes,” a result of consensus of American Diabetes Assosia-
tion, measurement of NC is recommended for clinical screening 
of OSA, especially in patients with T2DM. NC > than 17 inches 
in men and > 16 inches in women are significant cut-off values 
37. NC is also considered as independent factor for estimation 
of metabolic syndrome and insulin resistance, as NC > 38 cm 
predicted metabolic syndrome with 54% sensitivity and 70% 
specificity, and in prediction of OSA showed 58% sensitivity and 
79% specificity 38.
While polysomnography is considered a standard method for 
estimation of OSA, there are several criteria for diagnosis of 
diabetes and pre-diabetes: fasting blood glucose concentration > 
7 mmol/L, HbA1C > 6,5% or random blood glucose concentra-
tion > 11,1 mmol/L. Homeostasis model assesment of insulin 
resistance (HOMA-IR) score and HOMA-β score for quantify-
ing the β -cell function are also widely used for insulin resistence 
validation, especially in clinical and epidemiologic studies 39.
Many studies confirm the association in patohysiological factors 
between OSA, type 2 diabetes and obesity, and these conditions 
also share some independent risk factors, like age, inadequate 
nutrition, sedentary life style and genetic factors 7,15, 19. European 
Sleep Apnea Cohort Study results showed increased prevalence of 
OSA in diabetic subjects, and the severity of OSA was independ-
ent predictor of glycemic control, as the positive association 
between OSA severity indices and HbA1c levels was estimated in 
non-diabetic subjects 40. Ten studies, including extensive meta-
analysis of the SHSS Atherosclerosis Risk in Communities study 
have confirmed increased (1.35-fold) risk for OSA patients for 
developing T2DM regardless of body mass index (BMI) and age. 
The studies are well-described in the review of Reutrakul et al. 
15. Beside of being the independent risk factor for T2DM, OSA 
is more prevalent in adult patients with diabetes than in non-
diabetics, and prevalence of OSA in diabetics was 58-86% 13-15. 
Common pathophysiological mechanisms in osa 
and t2dm
Although it is still unknown whether presence of OSA can in-
duce T2DM, studies on animals and in heathly volunteers indi-
cate that intermittent hypoxia (IH) and sleep disturbance could 
be predisposing factors for impaired glucose metabolism, insulin 
resistance and T2DM in OSA patients. In study of N. Sokucu 
et al. that was performed in non-diabetic OSA patients, elevated 
blood level of hemoglobin A1c (HbA1c) has been found, and 
HbA1c level was negatively correlated with minimum oxyhemo-
globin desaturation levels (𝑟 = −0.302, 𝑃 = 0.018), and positively 
correlated with mean desaturation index (𝑟 =0.263, 𝑃 = 0.041) 
41. In extensive study including 1599 OSA patients without 
diabetes, Priou et al have observed positive correlation between 
severity of OSA and HbA1c levels, with dose-response relation-
ship between AHI and percentage of patients with HbA1c > 
6.0% ranging from 10.8% for AHI < 5 to 34.2% for AHI ≥ 50. 
increasing 42. In the same study, significance of AHI as independ-
ent factor remained high after adjustments for other factors, 
like age, sex, smoking habits, BMI, cardiovascular morbidity, 
daytime sleepiness, depression, and insomnia 42. Positive associa-
tion between level of HbA1c with percentage of sleep time with 
oxyhemoglobin saturation below 90% (𝛽 = 0.470, 𝑃 = 0.01) was 
also detected, and negative correlation was estimated with nor-
mal oxyhemoglobin saturation 43. Obstruction of upper airways, 
hypopnea and apnea cause lower oxygen blood saturation, inter-
mittent sleep with augmented stress, hormonal dysbalance and 
systemic inflammation. IH has a central role in pathogenesis of 
metabolic disturbance and diabetes in OSA, as it is at least partly 
responsible for decrease in insulin sensitivity, and decrease of 
glucose and oxygen utilisation at the level of the whole organism, 
which was confirmed in animal model and in humans. Group 
of Gozal et al. showed that sleep fragmentation with IH in mice 
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induced insulin resistance, increased oxygen stress and systemic 
inflammation, with release of proinflammatory cytokines from 
activated M1 macrophages 44. These factors were associated with 
beta-cell dysfunction and apoptosis 44,45. Cessation of the expo-
sure to IH has only partially reversed the metabolic changes and 
eventually was followed with the worsening of beta cell function 
46 In healthy human adults, acute IH induced transient elevation 
of blood glucose concentration 47 and impaired insulin sensitivity 
with an increased sympathetic nervous system activity 48. 
Intermittent hypoxia is not the only mechanism that impairs glu-
cose homeostasis in OSA patients. Although it is still unknown 
which factors in OSA patients may lead to diabetes, multiple 
factors are proposed as potential connection between IH and 
disturbed glucose metabolism: genetic factors, oxidative stress 
and inflammation, disturbed hypothalamo-pituitary-adrenal 
(HPA) axis with increased levels of circulating cortisol and free 
fatty acids, adipokines, elevated levels of endothelin-1 from dam-
aged vascular endothelium, and increased activity of sympathetic 
system 15. 
A recent genetic study with genotyping for single nucleotide 
polymorphysms (sRNPs) in patients with both OSA and T2DM 
indicated a possible link between polymorphysm of gene en-
coding apolipoprotein A-V (APOA5 rs3135506), particularly 
in overweight patients 15. APOA5 is an important regulator 
of triglyceride metabolism, and CC homozygotes of APOA5 
rs3135506 have predisposition for triglycerideridemia 49. Poly-
morphysms of APOA5 gene were previously linked to increased 
risk for diabetes, high BMI, ischemic stroke and cardiovascular 
disease 50.
The common link between factors and conditions that are 
connected both with OSA and T2DM might be the increased 
lipolysis and elevated levels of free fatty acids (FFA) in circula-
tion induced by IH. Obesity with plenty of circulating nutrients 
can certainly potentiate those metabolic impairments 51,52. It 
is known that high blood levels of FFA impair increase insulin 
resistance and glucose uptake by peripheral cells by multiple 
mechanisms on the level of peripheral cells 53 FFAs impair glu-
cose metabolic utilization by muscles, via inhibition of glycolytic 
enzymes 54, or inhibition of tyrosin kinase-mediated signal-
ing mechanisms downstream of insulin receptor 53. Increased 
circulating FFA levels also negatively affect insulin secretion from 
pancreatic beta cells 55 and may cause inflammatory response 
in beta cells via activation of Toll-like receptors 2 and 4, acting 
like damage-associated molecular patterns that induce produc-
tion of pro-inflammatory cytokines and recruit innate immune 
cells in the beta-cell surrounding 56. Beside hormones that can 
cause or contribute to hyperglycemia (cortisol, growth hor-
mone, epinephrine), activation of sympathetic nervous system, 
via β-adrenergic receptors, adipokines (resistin) and cytokines 
(TNFalpha, IL-6), adipocyte hypoxia is one of the factors that 
regulates lypolysis. A support for strong causal link between 
hypoxic condition, elevated circulating FFA and diabetes is seen 
in OSA patients after CPAP withrawal, in whom elevated levels 
of circulating FFA, glucose and cortisol were detected 52. In a 
recent study that included 118 participants with or without sleep 
disordered breathing, severity of hypoxia assessed by AHI was as 
independent factor, in positive correlation with adipocyte insulin 
resistance, lypolisis with elevated FFA levels, and decrease of 
glucose- and insulin-mediated suppression of lipolysis 53. 
Reversely, in patients with T2DM, presence of OSA increased 
lipolysis by 42% in comparison with patients with T2DM only, 
and this effect was independent from gender, BMI or waist cir-
cumference 51. The main source of circulating FFA are adipocytes 
which have an important role in glucose homeostasis and they 
exert many of their role via secretion of numerous adipokines, 
including resistin, adiponectin and leptin. Adipose tissue 
macrophages, especially those from visceral abdominal fat, are 
an important source of inflammatory cytokines including IL-6 
and TNF-α. These cytokines, in orchestra with other molecules 
involved in inflammation, like chemokines, adhesion molecules, 
C-reactive protein (CRP) and other acute-phase reactants, are 
found to be increased in OSA 57,58. They contribute to worsening 
of metabolic homeostasis and may increase the risk for cardiovas-
cular events in OSA patients 57-62. It is shown in model in vitro 
that exposure of adipocytes to intermittent hypoxia mimicking 
hypoxic episodes in OSA, results in expression of adipokines 
that participate in insulin resistance, impaired glucose tolerance.
and chronic mild inflammation 63. In patients with untreated 
OSA, elevated plasma levels of proinflammatory resistin and 
decreased plasma antiinflammatory adiponectin levels were 
detected 64,65 which was associated with elevated plasma levels of 
interleukin 6 and activation of nuclear factor kappa B (NF-κB) 
58. Also, production of a potent inflammatory cytokine, TNF-α 
in OSA patients, is positively associated with severity of OSA, 
and negatively associated with adiponectin. TNF-α may in-
crease a predisposition for T2DM and cardiovascular events as it 
decreases the synthesis of adiponectin which has a protective role 
in T2DM 66 Some studies indicate that treatment with CPAP 
efficiently reduces levels of TNF-α 67 and elevates adiponectin 
levels, although in this studies changes in insulin resistance index 
and BMI were not noticed 65. 
In a search for sensitive and specific biomarker that could predict 
the development of diabetes and cardiovascular complications 
in a individual with OSA, two different author groups were 
performed extensive literature meta-analysis of many plasma 
inflammatory biomarkers (C-reactive protein, TNF-α, IL-6, 
IL-8, adhesion molecules ICAM-1), oxidative stress biomark-
ers (NADPH oxidase, nitric oxide) and biomarkers of carbo-
hydrate and lipid metabolism (HbA1C, FFA and lipoproteins, 
levels of leptin, adiponectin and resistin) in OSA patients. All 
these different serum-derived parameters were proposed for the 
possible purpose of screening or clinical assessment of OSA 57, 
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68. However, still there is no ideal serum-specific biomarker that 
is consistently and specifically associated with both OSA and 
diabetes, and that could substitute time-consuming diagnosis 
with polysmonography and predict long-term complications 57,58. 
The results linking a specific serum parameter and diagnosis or 
prognosis were often contradictory or non-consistent, and may 
depend of the other individual factors like disease stage and other 
comorbidities 57,58. 
Chronic inflammatory reaction and oxidative stress can be linked 
with increased cortisol level in OSA patients. In OSA patients 
after withrawal of CPAP, increase of nocturnal levels of corti-
sol, with elevated levels of FFA and glucose was detected, and 
preexisting diabetes in OSA patient augmented hyperglycemic 
response. In the same study, increased sympathetic activity (heart 
rate) was also noticed 52. 
Glucose intolerance in OSA and risk for developing T2DM may 
be potentiated by the increased sympathetic activity in patients 
with OSA as a result of chemoreceptor reflex and stimulation of 
nucleus tractus solitarii caused with IH and sleep fragmentation 
69,70. Increased sympathetic tone negatively affects insulin secre-
tion by beta pancreatic cells, and contributes to the insulin resist-
ance. In OSA patients with prediabetes, it is found that one week 
of treatment with CPAP significantly decreased circulating levels 
of daytime and nighttime norepinephrine levels in plasma 71, 72 In 
obese patients with T2DM, presence of autonomic neuropathy 
caused by diabetes, increases risk for OSA, impairing mechanore-
ceptor reflex in upper airways 73.
The connection between metabolic, hormonal and autonom-
nous nervous system factors that are common to both OSA and 
diabetes may worse the clinical outcome of these both diseases 
separately, or potentiate clinical worsening when they are found 
simultaneously in the same patient. Beside this connection which 
is more investigated, last several years increased interest has 
grown with a scope on the possible increased risk for colorectal 
cancer in patients with OSA and T2DM. Results of Zhou et 
al. showed that in the T2DM patients with OSA circulating 
CEA levels were significantly higher (p<0.05) than that in those 
without OSA. Beside the fact that the AHI score was indepen-
dently linked with risk of increased CEA level in T2DM, in the 
male patients linear correlation was noticed between AHI score 
and CEA levels, with the highest CEA levels in the patients with 
AHI≥30 74. Furthermore, the highest CEA levels were measured 
in male patients with T2DM with obesity and had HbA1c level 
≥7% 74. Currently, the more data are required for the explanation 
of the possible pathogenetic connection between OSA, T2DM 
and colon cancer. Obesity may present the common link, as it 
is known that high-energy content and low-fiber nutrition can 
elevate levels of circulating IGF-1 and adipokine levels that can 
contribute to chronic inflammation, impaired immune system 
and growth of cancer cells 74. 
The role of cpap treatment in prevention of 
diabetes and its complications
It is still a question of debate whether CPAP, as a golden standard 
therapy for OSA, can prevent T2DM and its macrovascular and 
microvascular complications, and still there are no long-term 
data that consistently prove lower T2DM incidence in CPAP-
treated OSA patients 26. Some randomized controlled studies 
didn’t show any significant effect of CPAP on glycemic param-
eters. There are sveral possible reasons for that, including poor 
patient compliance to CPAP. In some studies, CPAP was applied 
for a relatively short period (3,6 and 4,3 hours per night) 75-77. 
Results of meta-analysis performed by Labarca et al. have showed 
that even more than 12 weeks of CPAP application didn’t im-
prove glycated hemoglobin levels 78. However, two studies where 
CPAP treatment was applied in 8-hour sleep period during at 
least 1 week reported statistically significant fall in fasting and 
24-hour glucose levels in patients with OSA and T2DM 71,72. Al-
though glycemic control was not significantly improved in mild 
or moderate OSA treatment by CPAP 79, in patients with severe 
OSA, CPAP treatment may prevent severe chronic diabetic com-
plications 80. Among ongoing studies, an extensive open-label, 
parallel-arm, randomised control trial cohort study SLEEP T2D 
is published as a preliminary project, with the aim to assess the 
impact of CPAP on microvascular complications in patients with 
T2DM during a period lasting at least two years 81.
Conclusion
In conclusion, obstructive sleep apnea and diabetes are both 
common diseases that coexist very often. They have common 
independent predisposing and pathogenetic factors, and the 
main of them is obesity. However, they can share many other 
pathogenetic factors like chronic inflammation, oxidative stress, 
hormonal changes and autonomic nervous system disbalance. 
This may lead to the additive or even synergistic effect in a pa-
tient, leading to accelerated development of atherosclerosis and 
its cardiovascular complications, and other possible conditions, 
including cancer. As OSA, obesity and diabetes type 2 are linked 
with increased risk for cardiovascular complications (including 
miocardial infarction, ischemic stroke, severe hypertension and 
arrhythmias), cardiovascular morbidity and mortality, special 
focus should be put on the early recognition of OSA simptoms 
in the patients with T2DM, and vice versa, patients with OSA 
should be regularly checked for presence of glucose intolerance 
or insulin resistance, in order to prevent long-term consequences. 
In all of these patients, special attention have to focused also on 
assesment and treatment of obesity.
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